epigallocatechin gallate has been researched along with Diabetic Glomerulosclerosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chakrapani, LN; Chandrasekar, N; Johnson, T; Kalaiselvan, P; Kannan, P; Karthikeyan, P; Mohan, T; Narasimhan, KKS; Periandavan, K; Ravi, DB; Srinivasan, A; Tamilarasan, B; Velusamy, P | 1 |
| Guo, L; Guo, W; Jin, H; Li, T; Liu, X; Liu, Y; Song, Y; Sun, W; Wang, F; Wu, H; Wu, J; Yang, T; Zhang, H | 1 |
| Chakrapani, LN; Johnson, T; Mohan, T; Periandavan, K; Singh, A; Srinivasan, AK; Velusamy, P | 1 |
| Hu, Z; Jiang, B; Li, H; Xiang, C; Xiao, X; Zhang, Y; Zhou, M | 1 |
| Chung, JH; Hong, R; Kim, CG; Kim, HL; Lee, BR; Maeng, YH; Shin, BC; Yoon, SP | 1 |
| Borges, CM; Duarte, DA; Lopes de Faria, JB; Lopes de Faria, JM; Papadimitriou, A | 1 |
| Kim, M; Oya, T; Yamabe, N; Yokozawa, T | 1 |
1 trial(s) available for epigallocatechin gallate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial.
Topics: Aged; Albuminuria; Apoptosis; Catechin; Cells, Cultured; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Pisum sativum; Podocytes; Polyphenols | 2016 |
6 other study(ies) available for epigallocatechin gallate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Role of Nrf2 dysfunction in the pathogenesis of diabetic nephropathy: Therapeutic prospect of epigallocatechin-3-gallate.
Topics: Animals; Catechin; Diabetes Mellitus; Diabetic Nephropathies; Humans; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Oxidative Stress | 2020 |
Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1.
Topics: Animals; Catechin; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Inflammation; Kelch-Like ECH-Associated Protein 1; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-E2-Related Factor 2; Oxidative Stress; RNA, Small Interfering; Signal Transduction; Up-Regulation | 2017 |
Impact of EGCG Supplementation on the Progression of Diabetic Nephropathy in Rats: An Insight into Fibrosis and Apoptosis.
Topics: Animals; Apoptosis; Catechin; Diabetic Nephropathies; Fibrosis; Humans; Kidney; Male; Prospective Studies; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta | 2017 |
Epigallocatechin‑3‑gallate protects from high glucose induced podocyte apoptosis via suppressing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Caspase 12; Catechin; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucose; Heat-Shock Proteins; Membrane Proteins; Mice; Podocytes; Protective Agents; WT1 Proteins | 2017 |
Protective effects of epigallocatechin gallate (EGCG) on streptozotocin-induced diabetic nephropathy in mice.
Topics: Animals; Blotting, Western; Body Weight; Catechin; Diabetic Nephropathies; Immunohistochemistry; Male; Mice; Mice, Inbred ICR; Random Allocation; Streptozocin | 2014 |
Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats.
Topics: Animals; Body Weight; Catechin; Cyclooxygenase 2; Diabetic Nephropathies; Fibronectins; Kidney; Male; NF-kappa B; Nitric Oxide Synthase Type II; Organ Size; Proteinuria; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Transforming Growth Factor beta | 2006 |